The content on this site is intended for healthcare professionals only
For the latest
cancer COVID-19 resources, click on this link
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Brain & nervous system
PARP inhibitors show promise for hard-to-treat breast cancers
2009 ASCO Annual Meeting
29 May - 2 Jun 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published: 25 Jun 2009
Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK
A study reports that women with BRCA deficient advanced breast cancer experienced tumour shrinkage after receiving the PARP inhibitor olaparib as a single agent.
War in Ukraine: Impacts on the Ukrainian cancer care system
Dr Andriy Hrynkiv
4 May 2022
Recurrent non-invasive breast tumours may not always be related to the primary l...
Dr Tanjina Kader - University of Melbourne, Melbourne, Australia
19 Apr 2022
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
13 Apr 2022
Preventive oncology nutrition for healthy carriers and BRCA1/2 + breast cancer p...
Dr Diana Artene - American Society for Nutrition, Bucharest, Romania
23 Feb 2022
Eye metastasis in breast cancer: Case report and review of literature
Dr Ereny Samwel Poles Saad - Assiut University, Asyut, Egypt
10 Feb 2022
The optimal approach after neoadjuvant treatment: The Lucerne toolbox
Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
3 Feb 2022
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs pl...
Prof Peter Schmid - Queen Mary University of London, London, United Kingdom
27 Jan 2022
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
Dr Aditya Bardia - Mass General Cancer Center, Boston, USA
22 Dec 2021
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgr...
Dr Sara Hurvitz - University of California, Los Angeles, USA
21 Dec 2021